These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 32732784)

  • 1. Medication Use and Health Care Utilization After a Cost-sharing Increase in Schizophrenia: A Nationwide Analysis.
    Hamina A; Tanskanen A; Tiihonen J; Taipale H
    Med Care; 2020 Sep; 58(9):763-769. PubMed ID: 32732784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Sharing Increase, Medication Adherence, and Hospitalizations in Schizophrenia Patients: A Natural Experiment.
    Serra-Burriel M; Hurtado I; Sanfélix-Gimeno G; García-Sempere A; Peiró S
    Clin Pharmacol Ther; 2021 Dec; 110(6):1490-1497. PubMed ID: 33973231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse clinical events among medicare beneficiaries using antipsychotic drugs: linking health insurance benefits and clinical needs.
    Fung V; Price M; Busch AB; Landrum MB; Fireman B; Nierenberg A; Dow WH; Hui R; Frank R; Newhouse JP; Hsu J
    Med Care; 2013 Jul; 51(7):614-21. PubMed ID: 23752219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antipsychotics Use Is Associated With Greater Adherence to Cardiometabolic Medications in Patients With Schizophrenia: Results From a Nationwide, Within-subject Design Study.
    Solmi M; Tiihonen J; Lähteenvuo M; Tanskanen A; Correll CU; Taipale H
    Schizophr Bull; 2022 Jan; 48(1):166-175. PubMed ID: 34286338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.
    Olivares JM; Rodriguez-Martinez A; Burón JA; Alonso-Escolano D; Rodriguez-Morales A;
    Appl Health Econ Health Policy; 2008; 6(1):41-53. PubMed ID: 18774869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimating the Impact of Adherence to and Persistence with Atypical Antipsychotic Therapy on Health Care Costs and Risk of Hospitalization.
    Jiang Y; Ni W
    Pharmacotherapy; 2015 Sep; 35(9):813-22. PubMed ID: 26406773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antipsychotic prescription filling in patients with schizophrenia or schizoaffective disorder.
    Reutfors J; Brandt L; Stephansson O; Kieler H; Andersen M; Bodén R
    J Clin Psychopharmacol; 2013 Dec; 33(6):759-65. PubMed ID: 24126686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Effectiveness of Adjunctive Psychotropic Medications in Patients With Schizophrenia.
    Stroup TS; Gerhard T; Crystal S; Huang C; Tan Z; Wall MM; Mathai C; Olfson M
    JAMA Psychiatry; 2019 May; 76(5):508-515. PubMed ID: 30785609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of paliperidone palmitate one-month formulation on relapse prevention in patients with schizophrenia: A post-hoc analysis of a one-year, open-label study stratified by medication adherence.
    Si T; Li N; Lu H; Cai S; Zhuo J; Correll CU; Zhang L; Feng Y
    J Psychopharmacol; 2018 Jun; 32(6):691-701. PubMed ID: 29764266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment Patterns, Healthcare Resource Utilization and Costs Among Schizophrenia Patients Treated with Long-Acting Injectable Versus Oral Antipsychotics.
    Shah A; Xie L; Kariburyo F; Zhang Q; Gore M
    Adv Ther; 2018 Nov; 35(11):1994-2014. PubMed ID: 30269292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of treatment patterns, healthcare resource utilization, and costs among young adult Medicaid beneficiaries with schizophrenia treated with paliperidone palmitate or oral atypical antipsychotics in the US.
    Manjelievskaia J; Amos TB; El Khoury AC; Vlahiotis A; Cole A; Juneau P
    J Med Econ; 2018 Dec; 21(12):1221-1229. PubMed ID: 30238806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medicaid prescription cost containment and schizophrenia: a retrospective examination.
    Farley JF
    Med Care; 2010 May; 48(5):440-7. PubMed ID: 20351586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rates and predictors of antipsychotic non-adherence and hospitalization in Medicaid and commercially-insured patients with schizophrenia.
    Lang K; Federico V; Muser E; Menzin J; Menzin J
    J Med Econ; 2013 Aug; 16(8):997-1006. PubMed ID: 23777223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medication Adherence, Health Care Utilization, and Costs in Patients With Major Depressive Disorder Initiating Adjunctive Atypical Antipsychotic Treatment.
    Broder MS; Greene M; Yan T; Chang E; Hartry A; Yermilov I
    Clin Ther; 2019 Feb; 41(2):221-232. PubMed ID: 30616973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of early nonadherence to oral antipsychotics on clinical and economic outcomes among patients with schizophrenia.
    Offord S; Lin J; Mirski D; Wong B
    Adv Ther; 2013 Mar; 30(3):286-97. PubMed ID: 23483449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antipsychotic Medication Adherence and Diabetes-Related Hospitalizations Among Medicaid Recipients With Diabetes and Schizophrenia.
    Egglefield K; Cogan L; Leckman-Westin E; Finnerty M
    Psychiatr Serv; 2020 Mar; 71(3):236-242. PubMed ID: 31744428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term Continuity of Antipsychotic Treatment for Schizophrenia: A Nationwide Study.
    Rubio JM; Taipale H; Tanskanen A; Correll CU; Kane JM; Tiihonen J
    Schizophr Bull; 2021 Oct; 47(6):1611-1620. PubMed ID: 34129663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of a limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia.
    Soumerai SB; McLaughlin TJ; Ross-Degnan D; Casteris CS; Bollini P
    N Engl J Med; 1994 Sep; 331(10):650-5. PubMed ID: 8052275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in treatment of newly treated schizophrenia-spectrum disorder patients in Taiwan from 1999 to 2006.
    Wu CS; Lin YJ; Feng J
    Pharmacoepidemiol Drug Saf; 2012 Sep; 21(9):989-96. PubMed ID: 22416032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.